share_log

Spectral Receives UKCA Authorization For Burn Indication Expected Commercialization In H2 2024

Spectral Receives UKCA Authorization For Burn Indication Expected Commercialization In H2 2024

Spectral 獲得 UKCA 燒傷指示授權,預計將於 2024 年下半年實現商業化
Benzinga ·  02/22 08:03

Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United Kingdom.

Spectral AI, Inc.(納斯達克股票代碼:MDAI)(“Spectral AI” 或 “公司”)是一家專注於醫學診斷以實現更快、更準確的傷口護理治療決策的人工智能(AI)公司,今天宣佈,其預測軟件DeepView AI-Burn已獲得英國合規評估(UKCA)的最後階段授權,用於幫助英國進行燒傷診斷。

"I am delighted to announce this achievement in our Company's evolution. The completion of this milestone will allow us to sell our DeepView System in the UK and we expect to swiftly deploy six devices in the UK for customer evaluation and to begin generating revenue in the second half of this year." said Wensheng Fan, the Company's Chief Executive Officer. "In addition, this regulatory authorization opens up the ability to expand partnerships with regions such as the Middle East that recognize the UKCA authorization." Revenue from commercialization in the UK in 2024 represents an addition to the $28 million revenue guidance previously communicated by the Company.

“我很高興地宣佈我們公司發展過程中取得的這一成就。這一里程碑的完成將使我們能夠在英國銷售我們的DeepView系統,我們預計將迅速在英國部署六臺設備進行客戶評估,並將在今年下半年開始創收。” 該公司首席執行官範文生說。“此外,該監管授權爲擴大與承認UKCA授權的中東等地區的合作伙伴關係開闢了能力。”2024年英國商業化收入是對該公司先前公佈的2,800萬美元收入指引的補充。

The DeepView System wound imaging device uses AI-enabled algorithms analyzing real-life patient wounds that assess clinically validated data points to distinguish between healthy and damaged tissue within seconds, unlike the current standard of care, which requires up to three to four weeks of evaluation. The technology establishes a high level of accuracy, 92%, in discerning whether tissue will heal naturally or necessitate surgical intervention, a process that is currently done by clinicians relying on visual observation and resulting in clinical judgement between only 50% to 75% accuracy.
"The current practice of prolonged and expensive observation with open wounds that risk infection before deciding on the best management of care is outdated," said Prof. Paul Chadwick, Spectral AI's Executive Vice President of the Company's United Kingdom subsidiary. "This protracted decision process burdens the patient as well as the healthcare system with unnecessary hospitalization time. The authorization of the DeepView System could effectively obviate the need for these long observation periods, accelerating the way we manage burn wounds in the UK."

DeepView System傷口成像設備使用基於人工智能的算法來分析現實生活中的患者傷口,評估經過臨床驗證的數據點,在幾秒鐘內區分健康和受損組織,這與目前的護理標準不同,目前的護理標準需要長達三到四周的評估。該技術在辨別組織是自然癒合還是需要手術干預方面確立了很高的準確度,爲92%,這一過程目前由臨床醫生依靠視覺觀察來完成,因此臨床判斷的準確性僅爲50%至75%。
Spectral AI英國子公司執行副總裁保羅·查德威克教授說:“在決定最佳護理管理之前,對有感染風險的開放性傷口進行長時間且昂貴的觀察的做法已經過時了。”“這種漫長的決策過程給患者和醫療保健系統帶來了不必要的住院時間。DeepView系統的授權可以有效地避免長時間的觀察,從而加快我們在英國管理燒傷的方式。”

UKCA marking is a certification system established by the UK government to ensure that products meet specified standards for sale in the UK (England, Wales, and Scotland). The DeepView AI-Burn is currently indicated for individuals aged eighteen and above. The Company aims to extend its technology to benefit pediatric populations and is continuing to initiate case studies and case series with surgeons at leading burn centers.

UKCA 標誌是英國政府建立的認證體系,旨在確保產品符合在英國(英格蘭、威爾士和蘇格蘭)銷售的特定標準。DeepView AI-Burn 目前適用於十八歲及以上的個人。該公司旨在擴展其技術,使兒童受益,並將繼續與主要燒傷中心的外科醫生一起啓動案例研究和案例系列。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論